{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T12:11:20Z","timestamp":1788783080260,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100020424","name":"Weill Cornell Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020424","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.012","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T15:07:50Z","timestamp":1786806470000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies: A Phase II Study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4552-0109","authenticated-orcid":false,"given":"Mohammad","family":"Alhomoud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2245-4068","authenticated-orcid":false,"given":"Franco Castillo","family":"Tokumori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Chokr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Fein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Usama","family":"Gergis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrienne","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingmei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0897-3790","authenticated-orcid":false,"given":"Alexandra","family":"Gomez-Arteaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6033-0747","authenticated-orcid":false,"given":"Tsiporah","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-6452","authenticated-orcid":false,"given":"Zhengming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Scandura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen van","family":"Besien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.012_bib0001","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.08.012_bib0002","doi-asserted-by":"crossref","first-page":"6283","DOI":"10.1182\/bloodadvances.2020003418","article-title":"How much has allogeneic stem cell transplant-related mortality improved since the 1980s? A retrospective analysis from the EBMT","volume":"4","author":"Penack","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.012_bib0003","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41409-019-0624-z","article-title":"Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors","volume":"55","author":"Styczy\u0144ski","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0004","doi-asserted-by":"crossref","first-page":"e573","DOI":"10.1016\/S2352-3026(19)30158-9","article-title":"Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis","volume":"6","author":"Shouval","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0005","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1200\/JCO.20.03380","article-title":"Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced myelodysplastic syndrome","volume":"39","author":"Nakamura","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0006","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0007","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdp309","article-title":"Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006-2010","volume":"21","author":"Pulte","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0008","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41408-024-01143-2","article-title":"Current status and research directions in acute myeloid leukemia","volume":"14","author":"Kantarjian","year":"2024","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2026.08.012_bib0009","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0010","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-09-382770","article-title":"5-azacytidine and decitabine exert proapoptotic effects on neoplastic mast cells: role of FAS-demethylation and FAS re-expression, and synergism with FAS-ligand","volume":"119","author":"Ghanim","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0011","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1158\/2159-8290.CD-13-0117","article-title":"Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma","volume":"3","author":"Clozel","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtct.2026.08.012_bib0012","first-page":"3730","article-title":"Concurrent DNA hypermethylation of multiple genes in acute myeloid leukemia","volume":"59","author":"Melki","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.jtct.2026.08.012_bib0013","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1182\/blood.V97.9.2823","article-title":"Methylation profiling in acute myeloid leukemia","volume":"97","author":"Toyota","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0014","first-page":"3757","article-title":"Singal R: 5-azacytidine reverses drug resistance in bladder cancer cells","volume":"31","author":"Ramachandran","year":"2011","journal-title":"Anticancer Res"},{"key":"10.1016\/j.jtct.2026.08.012_bib0015","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/annonc\/mdp569","article-title":"Down-regulation of mitochondrial ATPase by hypermethylation mechanism in chronic myeloid leukemia is associated with multidrug resistance","volume":"21","author":"Li","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0016","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-09-1125","article-title":"Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas","volume":"15","author":"Elias","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.08.012_bib0017","first-page":"3207","article-title":"Methylation mediated silencing of TMS1 in breast cancer and its potential contribution to docetaxel cytotoxicity","volume":"29","author":"Gordian","year":"2009","journal-title":"Anticancer Res"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.012_bib0018","first-page":"28","article-title":"5-Aza-2\u2019-deoxycytidine as a differentiation inducer in acute myeloid leukaemias and myelodysplastic syndromes of the elderly","volume":"4 suppl","author":"Pinto","year":"1989","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0019","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1182\/blood-2010-11-320093","article-title":"Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML","volume":"118","author":"Scandura","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0020","doi-asserted-by":"crossref","first-page":"12342","DOI":"10.18632\/oncotarget.12511","article-title":"Better transplant outcome with pre-transplant marrow response after hypomethylating treatment in higher-risk MDS with excess blasts","volume":"8","author":"Yahng","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jtct.2026.08.012_bib0021","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1007\/s12253-015-9933-8","article-title":"Impact of prior azacitidine on the outcome of allogeneic hematopoietic transplantation for myelodysplastic syndrome","volume":"21","author":"Oshikawa","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"10.1016\/j.jtct.2026.08.012_bib0022","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s12185-014-1549-3","article-title":"Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes","volume":"99","author":"Kim","year":"2014","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0023","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/bmt.2009.134","article-title":"5-azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation","volume":"45","author":"Field","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1080\/10428194.2019.1605070","article-title":"Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome","author":"Modi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.08.012_bib0025","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"Dohner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0026","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0027","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.jtct.2026.08.012_bib0028","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0029","doi-asserted-by":"crossref","first-page":"6823","DOI":"10.1093\/nar\/gki987","article-title":"Analysis of repetitive element DNA methylation by MethyLight","volume":"33","author":"Weisenberger","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtct.2026.08.012_bib0030","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1182\/blood-2012-05-429175","article-title":"Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia","volume":"120","author":"Yan","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0031","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: an open-source package for R and S+ to analyze and compare ROC curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.jtct.2026.08.012_bib0032","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/j.bbmt.2014.05.010","article-title":"Upfront allogeneic stem cell transplantation after reduced-intensity\/nonmyeloablative conditioning for patients with myelodysplastic syndrome: a study by the Soci\u00e9t\u00e9 Fran\u00e7aise de Greffe de Moelle et de Th\u00e9rapie Cellulaire","volume":"20","author":"Damaj","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0033","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1080\/10428194.2019.1605070","article-title":"Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome","volume":"60","author":"Modi","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2026.08.012_bib0034","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.bbmt.2019.03.011","article-title":"Comparison between upfront transplantation and different pretransplant cytoreductive treatment approaches in patients with high-risk myelodysplastic syndrome and secondary acute myelogenous leukemia","volume":"25","author":"Schroeder","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0035","doi-asserted-by":"crossref","first-page":"5728","DOI":"10.1200\/JCO.2005.15.602","article-title":"Fludarabine, melphalan, and alemtuzumab conditioning in adults with standard-risk advanced acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"van Besien","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.08.012_bib0036","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.bbmt.2009.01.021","article-title":"Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes","volume":"15","author":"van Besien","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.012_bib0037","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3324\/haematol.2009.013920","article-title":"Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia","volume":"95","author":"Craddock","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.08.012_bib0038","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","article-title":"Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes","volume":"26","author":"Bernard","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.jtct.2026.08.012_bib0039","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/hematology.2022000354","article-title":"Transplant for TP53-mutated MDS and AML: because we can or because we should?","volume":"2022","author":"Versluis","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2026.08.012_bib0040","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1182\/bloodadvances.2024014499","article-title":"TP53-mutant variant allele frequency and cytogenetics determine prognostic groups in MDS\/AML for transplantation","volume":"9","author":"Lontos","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.012_bib0041","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","article-title":"In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia","volume":"116","author":"Choi","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0042","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.3324\/haematol.2012.074823","article-title":"The effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndrome","volume":"98","author":"Costantini","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jtct.2026.08.012_bib0043","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2026.08.012_bib0044","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00002018-200124010-00003","article-title":"Anticancer drug-induced kidney disorders","volume":"24","author":"Kintzel","year":"2001","journal-title":"Drug Saf"},{"key":"10.1016\/j.jtct.2026.08.012_bib0045","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1182\/blood.V57.1.182.182","article-title":"5-Azacytidine and renal tubular dysfunction","volume":"57","author":"Peterson","year":"1981","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:22:48Z","timestamp":1788780168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":45,"alternative-id":["S2666636726006159"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.012","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epigenetic Priming with Azacitidine Prior to Allogeneic Hematopoietic Stem Cell Transplantation for Myeloid Malignancies: A Phase II Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}